Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab

Yosuke Kawashima; Shingo Nishikawa; Hironori Ninomiya; Reiko Yoshida; Natsuki Takano; Tomoyo Oguri; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Yuichi Ishikawa; Makoto Nishio

doi:10.2169/internalmedicine.1673-18

CASE REPORTS

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab

Yosuke Kawashima, Shingo Nishikawa, Hironori Ninomiya, Reiko Yoshida, Natsuki Takano, Tomoyo Oguri, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Ishikawa, Makoto Nishio

Author information

Yosuke Kawashima
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Shingo Nishikawa
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Hironori Ninomiya
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Japan
Reiko Yoshida
Division of Clinical Genetic Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, Japan
Natsuki Takano
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Tomoyo Oguri
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Satoru Kitazono
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Noriko Yanagitani
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Atsushi Horiike
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Fumiyoshi Ohyanagi
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Yuichi Ishikawa
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Japan
Makoto Nishio
Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan

Keywords: Lynch syndrome, MSI-H, nivolumab

JOURNAL OPEN ACCESS

2019 Volume 58 Issue 10 Pages 1479-1484

DOI https://doi.org/10.2169/internalmedicine.1673-18

Details

Abstract

Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends to be expressed at higher levels in MSI-H cancers than in microsatellite-stable cancers. MSI-H cancer patients are therefore considered to be susceptible to immune checkpoint blockade. We herein report for the first time a case of lung adenocarcinoma with Lynch syndrome and the response to nivolumab.

Corresponding author

Register with J-STAGE for free!